Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients
about
sameAs
Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategyPhenytoin as a novel anti-vitiligo weaponGenetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and LociVitiligo: interplay between oxidative stress and immune systemT lymphocytes targeting native receptorsHuman dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Vitiligo puzzle: the pieces fall in place.Analysis of oxidative stress status, catalase and catechol-O-methyltransferase polymorphisms in Egyptian vitiligo patientsIn vivo vitiligo induction and therapy model: double-blind, randomized clinical trial.Immunotherapy of human cancers using gene modified T lymphocytes.GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.Tumor necrosis factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibilityGILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.Self-representation in the thymus: an extended view.The Newest Hypothesis about Vitiligo: Most of the Suggested Pathogeneses of Vitiligo Can Be Attributed to Lack of One Factor, Zinc-α2-GlycoproteinExpression of Epidermal c-Kit+ of Vitiligo Lesions Is Related to Responses to Excimer Laser.Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis.Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligoIdentification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients.GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity.Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets.Vitiligo, reactive oxygen species and T-cells.Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductaseVitiligo: a review of the published work.Vitiligo: what's new in the psycho-neuro-endocrine-immune connection and related treatments.Successful management of insulin allergy and autoimmune polyendocrine syndrome type 4 with desensitization therapy and glucocorticoid treatment: a case report and review of the literature.Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.Hypothesis: zinc can be effective in treatment of vitiligo.Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo.Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.Halo naevi with associated vitiligo-like depigmentations: pathogenetic hypothesis.Identification of the Risk HLA-A Alleles and Autoantigen in Han Chinese Vitiligo Patients and the Association of CD8+T Cell Reactivity with Disease Characteristics
P2860
Q24814910-05246754-F2F0-4EED-8AC6-3C6ED10785AEQ24815549-1325BF55-C2EB-4BA5-BEE9-B92609E6A121Q26766384-32728300-3358-45BA-B721-960FC23F486DQ26824504-63C65B86-C723-45FB-AE05-C04029472816Q26853345-466DDD88-A5AA-463E-8449-6BFB93683D8BQ30426385-FD6DB4EE-53F1-4815-940B-B9964DF7B9D1Q33344607-54260041-A211-4845-924B-FC1973F8C6CDQ33734642-067057CE-7B9A-4897-B04F-749FA70421BEQ34043986-D13EFA23-4B34-4360-88AE-6A14CBECCD31Q34188383-B94D4CA4-8A13-4B76-8F27-EF0366D312BAQ34692289-6DE7FF3C-4418-41FE-816F-F7F99D72159FQ35060678-9E425D82-6C6F-4CAE-B870-0209BAC2EA53Q35552274-9049DEF0-1C67-4423-8854-F6BA3F08D6F7Q35877206-E632B0CF-50D4-441E-AA16-B09CECF71E61Q36072254-C725B67D-CA9F-4B3C-9C55-87D1D8204F51Q36094556-29407F37-8F51-495C-8496-DFC1DDAF2AA5Q36652524-9DA9181C-7240-44CC-A5D5-3737E12B1272Q37240967-B1D786CF-F4B4-4BAF-93EC-4D186EDB72FEQ37271641-4367253E-1AC3-45F4-9EF7-376BDAD32848Q37399612-C63E0CA6-EA1C-49F4-A112-FEE9B529385DQ37453613-4AFAD062-9DD6-499C-970D-8BAED2FE631FQ37611016-6C5A340A-1BC1-4722-89E8-618C9D200E70Q37801388-9780EC3D-D8A4-4A24-ACBE-344986672E05Q37867108-9B424735-843C-44E5-8FED-97DBE1215C23Q37888578-08636F37-C6A4-4A27-8457-9F8C0083C7C3Q38233632-A26D5426-B0D4-49DC-AD4F-CD0C31718002Q38303637-9BD7BE9A-0EB7-4950-9E1F-B04E28043E3FQ38943432-4DCA4DA8-65C9-4598-949B-4BDA67F5687EQ39268576-2F46B733-816D-4169-926F-6B959A3F252CQ39412203-AD4DDE2E-6DF5-426B-AF45-04B9DB2FC5A2Q39419931-C11B35BE-BF64-484F-AD77-974EE0155225Q45344644-762A8A42-F4CC-4D76-B72C-EE32C258043AQ58735924-A3D1AD17-8EA3-4367-AA87-004FFB5C48B6
P2860
Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@ast
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@en
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@nl
type
label
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@ast
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@en
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@nl
prefLabel
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@ast
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@en
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@nl
P2093
P3181
P1476
Cytotoxic T lymphocyte reactiv ...... -A2-positive vitiligo patients
@en
P2093
Brian H Barber
David Spaner
Mark A DeBenedette
Neil H Shear
Rochelle L Mandelcorn-Monson
Suryaprakash Sambhara
P3181
P356
10.1046/J.1523-1747.2003.12413.X
P407
P577
2003-09-01T00:00:00Z
P5875
P6179
1016692681